Clinical trial
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
NCT00350636 · Watson Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00350636 |
|---|---|
| Title | A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo |
| Official title | Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension |
| Lead sponsor | Watson Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Overactive Bladder |
| Intervention type | Drug, Other |
| Interventions | Oxybutynin topical gel, Placebo topical gel |
| Enrollment | 789 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jul 11, 2006 |
| Last update posted | May 10, 2010 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: